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Abstract
Loss of power and clear description of treatment differences are key issues in designing and
analyzing a clinical trial where non-proportional hazard is a possibility. A log-rank test may be
inefficient and interpretation of the hazard ratio estimated using Cox regression is potentially
problematic. In this case, the current ICH E9 (R1) addendum would suggest designing a trial
with a clinically relevant estimand, e.g., expected life gain. This approach considers appropriate
analysis methods for supporting the chosen estimand. However, such an approach is case spe-
cific and may suffer lack of power for important choices of the underlying alternate hypothesis
distribution. On the other hand, there may be a desire to have robust power under different
deviations from proportional hazards. We would contend that no single number adequately de-
scribes treatment effect under non-proportional hazards scenarios. The cross-pharma working
group has proposed a combination test to provide robust power under a variety of alternative
hypotheses. These can be specified for primary analysis at the design stage and methods ap-
propriately accounting for combination test correlations are efficient for a variety of scenarios.
We have provided design and analysis considerations based on a combination test under dif-
ferent non-proportional hazard types and present a straw man proposal for practitioners. The
proposals are illustrated with real life example and simulation.
Key Words: Non-proportional hazards, Log-rank test, Weighted log-rank test, Combination test,
Clinical trial design
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1 Introduction
A time to event endpoint is the primary outcome of interest in many clinical trials. For such trial,
each subject is either experience an event of interest (e.g., disease progression or death) or censored.
Commonly used statistical methods for comparing two survival curves in a randomized trial are the
Kaplan-Meier survival plot [1], log-rank test [2], and Cox regression [3]. The performance of the
log-rank test and Cox regression heavily depend on the proportional hazards (PH) assumption. In
reality, the PH assumption is often not met. For example, recent immuno-oncology therapies pose
unique challenges to the trial design where a delayed separation of the Kaplan-Meier curves have
often been observed, potentially resulting in a violation of proportional hazards (PH) assumption
( [4], [5], [6], [7]).
Since treatment differences under non-proportional hazard (NPH) constitute a broad class of
alternative hypotheses, finding one test and estimate of treatment benefit that are consistently
meaningful and provide good statistical power in multiple situations is challenging. Well known
NPH types observed in clinical trials are delayed effect, crossing survival, and diminishing effect
over time. While there may be speculation about the nature of treatment effect at the time of
study design, we have found that it can often be wrong. This further complicates the trial design
and treatment effect quantification. Therefore, a suitable design and analysis method for time to
event data with potential NPH must be able to describe multiple alternatives in a meaningful way
as well as provide competitive power to optimal tests across many scenarios. In addition, a single
treatment effect summary is not adequate to capture the time dependent nature of the benefit. We
need measures beyond a simple hazard ratio or restricted mean survival time (RMST) to quantify
and communicate the treatment effect.
The goal of this paper is to guide practitioners about strengths and limitations of the avail-
able methods of design and analysis of clinical trial with potential NPH. We evaluate them as a
candidate for primary analysis in the confirmatory studies. These are meant as straw man propos-
als for initiating a general discussion with different stakeholders. While considerable thought and
background investigation has gone into this proposal by a cross-pharma working group, it is not
endorsed by regulatory authorities. Project specific customization is necessary to fulfill the needs
in a particular situation.
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The rest of the paper is structured as follows. We start with a brief overview of the statistical
methods available in the literature and their merit as the primary analysis in confirmatory trials.
This is followed by some recommendations for analysis and design approaches when NPH is plau-
sible. Both the sections are complemented with illustrative examples. Discussion and concluding
remarks are in the last section.
1.1 Overview of Available Methods
There is a vast literature available on the analysis of time to event data in presence of NPH. In
this paper, we mainly focus on the statistical methods related to drug development. Till date,
the log-rank (LR) test is the regulatory accepted standard test for comparing two survival curves.
Being nonparametric in nature, the LR test is statistically valid when the PH assumption is not
met, but it has poor power in certain situations [4]. Moreover, the hazard ratio (HR) generated by
the Cox proportional hazards model has limited interpretation as a treatment effect summary when
data fails to support the PH assumption. Possible alternative is a general class of weighted log-rank
test (WLR) introduced by Fleming-Harrington (FH) (Gρ,γ) [8] and weighted hazard ratio (WHR)
[8, 9]. Other available options are piecewise LR test [10, 11], modestly weighted LR test (mWLRT)
[12] and the piecewise HR. For rank based methods other than LR test, model parameters (e.g.,
weight function, intervals) play an important role in the successful implementation of all these
methods. Therefore, achieving robust power under wide number of NPH alternative is difficult.
Recently, Kaplan-Meier (KM) based methods such as difference in milestone survival rates at
fixed time points [13] and restricted mean survival time (RMST) [14, 15, 16] have become popular
to the non-statisticians for its intuitive and simplistic interpretation under NPH. Weighted Kaplan-
Meier test (WKM) [17] and restricted mean time lost (RMTL) are the other methods in the same
class. Performance of KM based methods depend on the length of study period (τ) and censoring
pattern. Simulation studies have shown that the power gain for the WKM and RMST are minimal
in comparison to the LR test when there is a delayed effect [18]. Moreover, the time point(s) for
milestone survival analysis needs to be chosen carefully for proper clinical interpretation.
Cox regression has been widely used in clinical trial for treatment effect estimation. A natu-
ral extension of Cox regression model for NPH setting is including a time varying coefficient for
treatment (CoxTD) [19]. However, one major challenge of this approach is the specification of
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appropriate “time function” before trial begins. Putter et al 2005 [19] also suggested “log-time”
function as a “reasonable” choice to diminish the influence of very early events. An extensive simu-
lation study in Callegaro and Spiessens 2017 [20] showed that the CoxTD model does not perform
well in terms of power when the underlying survival pattern is delayed treatment effect. Moreover,
the HR as a continuous function of time for the primary treatment effect summary is not appealing
to clinicians, regulators and patients.
Combination tests provide robust testing of hypothesis approach when the type of NPH is
unknown. In a combination test, multiple test statistic are considered at the same time to handle
possibilities of different types of NPH when trial data emerges. A combination test can combine
multiple rank-based tests [21] or rank-based tests with KM based tests [22]. Notable works in this
area include Breslow et al 1989 [23], Lee 1996 [24], Chi and Tsai 2000 [22], Lee 2007 [21], Logan
2008 [25], Yang and Prentice 2010 [26], Karrison 2016 [27], Callegaro and Spiessens 2017 [20],
and Lin et. al 2020 [18]. Moreover, combination tests do not require pre-specification of a unique
test while designing the trail. Due to the flexibility of the test statistic, the combination test often
provides robust power under wide class of alternative hypotheses. We have discussed utilities of
one particular combination test further in Section 2.1.1 and 2.1.2.
Other important work in this area are accelerated failure time (AFT) model [28, 29, 30] and
net benefit [31, 32]. Further details of different approaches are provided in the supplementary
appendix.
2 Analysis Approaches of Clinical Trials with Non-proportional
Hazards
A key challenge is to specify the primary analysis of a clinical trial when there are considerable
uncertainties regarding the actual NPH type. Recent trials show that a delayed effect is common
in immuno-oncology [4]. Other NPH types such as crossing survival and diminishing effects have
been also observed in different therapeutic areas. At the time of trial design, PH, a delayed effect
with unknown delay or even crossing hazards with an uncertain degree and timing of crossing can
all be plausible. A good primary analysis method for trials with potential NPH needs to take
into account all the uncertainties mentioned above to provide robust statistical inference. In this
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section, we propose a few candidates for testing the primary endpoint in a confirmatory trial along
with relevant treatment effect quantifiers. We provide three real life examples for illustration.
2.1 Choice of Primary Analysis Method for a Confirmatory Trial
Based on the ICH E9 guideline [33], the primary analysis of a trial needs to be planned prior to
enrolling patients. This increases the degree of confidence in the final results and conclusions of
the trial. A primary analysis involves both testing and estimation of treatment effect that goes to
the label of a drug if approved. With potential NPH, it is difficult to specify a statistical method
that can provide consistently high power across PH and different NPH scenarios.
At first, we perform a qualitative evaluation of the methods described in Section 1.1 as possible
candidates for the hypothesis testing in the primary analysis of a confirmatory trial. The purpose
of this comparison is to help statisticians understand the merits and shortcomings of each method
as a candidate for the primary analysis. We consider the following four metrics as the basis for this
comparison. Table 1 summarizes the advantages and disadvantages of each approach.
1. Type I error: Controlling type I error at a specific level of significance (e.g., 2.5%) under the
null hypothesis H0: SC(t) = ST (t) for all t. Here SC(t) and ST (t) are the underlying survival
functions for control and treatment group respectively.
2. Robust power: Showing resilience in terms of statistical power when the PH assumption
is violated. Often a statistical test suffers a power loss when the nature of the underlying
treatment effect is not anticipated.
3. Treatment effect Interpretation: Interpretable treatment effect summary under various types
of PH and NPH
4. Non-statistical Communication: Easy to understand by non-statisticians
[Table 1 about here.]
Based on the assessment above WKM, milestone survival, RMST, CoxTD, and combination
tests are potential candidates for hypothesis testing method in the primary analysis of a confirma-
tory trial when NPH is expected. But, WKM, CoxTD, milestone survival and RMST fail to show
6
robust power under a wide class of alternatives [18], [20]. In the next subsection we will introduce
a new combination test for confirmatory trials which is an improvement over the available tests
and provides robust power under various NPH scenarios. If NPH is not expected, we recommend
the use of traditional LR test and HR for the primary analysis.
2.1.1 Robust MaxCombo Test
We propose a new combination test as an alternative choice for primary analysis of a confirmatory
trial when NPH is a possibility. The test is based on multiple Fleming-Harrington WLR test
statistics and chooses the best one adaptively depending on the underlying data. The main objective
of this test is to provide robust power for primary analysis under different scenarios. We refer to it
as the MaxCombo test. This idea is motivated from the work by Yang and Prentice 2010 [26] and
Lee 2007 [21].
The MaxCombo test considers the maximum of four correlated Fleming-Harrington WLR test
statistics; G0,0 (LR test), G0,1, G1,1, and G1,0 (Prentice-Wilcoxon) together provides a robust
test under different scenarios including PH, delayed effect, crossing survival, early-separation, and
mixture of more than one NPH type scenarios as an alternative. Other weight function for WLR
test can also be considered depending on the expected outcome. We propose alternate weights
as another option in the next sub-section. By construction MaxCombo is less dependent on the
underlying shape of the survival curve than a single WLR and shows good power across many
alternatives with respect to the optimal design for each alternative.
The type I error and power calculation require the joint distribution of four WLR statistics.
Under the null hypothesis, joint distribution of G0,0, G0,1, G1,1, and G1,0 asymptotically follows
a multivariate normal distribution [27]. The p-value of MaxCombo test is calculated by using
a 4-dimensional multivariate normal distribution. This calculation can be done using efficient in-
tegration routine in standard statistical software like R and SAS [34]. Further details of the
variance-covariance calculation are provided in Appendix A. MaxCombo is flexible enough to in-
corporate other weighting schemes as well. However, the variance-covariance structure may not
be in closed form and requires intensive computation. The type I error and power calculation
for MaxCombo do not have a closed form expression. Therefore, a simulation based approach is
suggested to calculate the operating characteristics.
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An extensive simulation study under the null hypothesis and different treatment effect scenarios
was performed by the cross-pharma working group (Lin et. al. 2018 [18]). The simulation study
considered varied enrollment patterns, number of events, and total study duration. It showed that
the type I error is well protected below 2.5% under the null hypothesis (no treatment effect). The
simulation study also demonstrated robust power of the MaxCombo test under different alterna-
tives. It showed a clear benefit over LR, WKM and RMST in terms of power in presence of the
delayed effect and crossing survival. The proposed MaxCombo also showed benefit over the Lee
2007 [21] combination test when the underlying hazard is delayed effect with converging tails [18].
The Lee’s method [21] is computationally intensive than MaxCombo due to the use of simulation.
Moreover, the power loss of the MaxCombo test was minimal (3-4%) as compared to the LR test
when the underlying treatment effect is PH. In summary, the MaxCombo test fulfills the necessary
regulatory standards and is suitable for a confirmatory trial with potential NPH.
2.1.2 Additional Investigation of MaxCombo Test
We have further investigated the properties of the MaxCombo test in extreme scenarios such as
strong null [12, 35] and severe late crossing. A strong null scenario refers to a situation when the
survival distribution of treatment group is uniformly inferior to the control group (i.e., SC(t) ≥
ST (t) for all t). Two different strong null scenarios are considered here. The First scenario is from
the Magirr and Burman 2019 [12] paper and referred as strong null 1. We have also explored another
extreme scenario ( referred as strong null 2) which is adopted from the Freidlin and Korn 2019
[35]. For the severe late crossing scenario, the treatment group shows a late and marginal survival
benefit over the control group which makes the overall treatment effect clinically questionable. Each
scenario is evaluated with 20,000 simulations.
Following Magirr and Burman 2019 [12], we have assumed a two-arm randomized control trial
with 100 patients per arm, recruited at a uniform rate over 12 months. For the control arm, survival
data is generated using an exponential distribution with a median of 15 months. The final cut-off
date for each simulation is the calendar time of 36 months after the start of the study. All patients
alive at that point are censored at the cut-off date. The following scenarios are considered for the
treatment arm using two piece exponential distribution:
a) Strong null 1: For the first 6 months, the hazard rate is log 2/9 = 0.077 (i.e, hazard ratio 1.67
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(treatment vs control)). After 6 months, the hazard rate is approximately 0.04 (i.e, hazard
ratio 0.87 (treatment vs control)). This ensures that the survival probability for patients
in control arm is always better than in treatment arm. The curves meet at the 36 month.
months.
b) Severe late crossing: For the first 6 months, the survival rate is log 2/9 = 0.077 (i.e, hazard
ratio 1.67 (treatment vs control)). After 6 months the hazard rate is approximately 0.036
(i.e, hazard ratio 0.79 (treatment vs control)). This ensures that the survival probabilities
for patients in control arm is better than in treatment arm till month 27. The survival
probability of the treatment arm is marginally better than control arm afterwards. However,
the treatment effect in this scenario is not clinically relevant.
For the strong null 2, we have assumed two-arm randomized control trial with 1000 patients per
arm, recruited instantaneously. For the control arm, survival data is generated using an exponential
distribution with a median of 2.7 years (i.e., constant hazard rate 0.25). The final cut-off date for
each simulation is the calendar time of 5 years after the start of the study. All patients alive at
that point are censored at the cut-off date. For the treatment arm, survival data is generated using
a two piece exponential distribution. For the first 1.2 months, the hazard rate is log 2/0.1732868 =
4 (i.e, hazard ratio 16 (treatment vs control)). After 1.2 months, the hazard rate is approximately
0.19 (i.e, hazard ratio 0.76 (treatment vs control)). This set up is consistent with the one proposed
by Freidlin and Korn 2019 [35].
The underlying survival distributions of treatment and control arms under two strong null and
severe late crossing scenarios are shown in Figure 1. We presume that the trials run with either
of these scenarios would most likely be stopped early by a data monitoring committee (DMC) due
to the safety concerns if these scenarios are observed in real life [36]. Strong null situations are
unlikely in the confirmatory trials. Therefore, these findings should not be mixed with type-I error
assessment.
[Figure 1 about here.]
Simulations show that the probability of rejecting null hypothesis is as low as 2.1% for the
MaxCombo test under the strong null 1 scenario due to the multiplicity adjustment. For the severe
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late crossing scenario, the probability of rejecting null hypothesis is also small (5.0%). The results
are similar if the recruitment period is 6 months (strong null 1: 2.3% and severe late crossing:
5.8%). This further confirms favorable operating characteristics of the MaxCombo test under these
extreme scenarios. However for the strong null 2, the probability of rejecting null hypothesis goes
up to 48.9% due to it’s extreme nature.
If extreme scenarios like severe late crossing and strong null 2 are of major concern, one can
consider an alternatives weights for WLR in MaxCombo test. For example, we have investigated
a modified MaxCombo test with G0,0, G0,0.5, G0.5,0.5, and G0.5,0. The probabilities of rejecting
null hypothesis with modified MaxCombo are reduced significantly to 2.6% under the severe late
crossing scenario and 1.8% under the strong null 2. The power loss is also minimal as compared
to the original MaxCombo test. Furthermore, we looked into the proportional hazard (PH) and
delayed effect (DL) defined by Magirr and Burman 2019 [12] to understand the impact on power.
The power of the modified MaxCombo test is comparable with the original MaxCombo test. For PH
and DL scenarios; the powers for modified MaxCombo test are 76.1% and 78.2% respectively. The
powers for original MaxCombo test are 74.4% and 79.9% respectively. The results are still superior
to the LR and modestly weighted LR test [12]. Therefore, the modified MaxCombo test with
more moderate down-weighting is a good alternative if practitioners want to have strict control for
extreme scenarios like severe late crossing and strong null 2. Note that, both statistically significant
and clinically relevant results are required for regulatory approval, regardless of the testing strategy
used.
2.2 Specification of the Primary Analysis
The primary analysis involves both hypothesis testing and estimation of treatment effect. Under
NPH, a single summary statistic measure (e.g. HR or RMST) fails to capture the time dependent
treatment effect and is heavily dependent on the follow-up duration. Therefore, multiple treatment
effect summaries are critical to summarize and understand the overall risk-benefit profile. Also, it
is important that sufficient follow-up is available to characterize both short- and long-term effects.
We propose a three step approach for primary analysis using the MaxCombo test when there is
a chance of observing NPH. The main goals of the proposed approach are the use of a robust
test and provide appropriate treatment effect summaries. In spite of the early specification, the
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proposed approach reports the best treatment effect summaries in adaptive manner based on the
data. Similar approaches based on the LR test and CoxTD were discussed by Royston and Parmer
2011 [14] and Campbell and Dean 2013 [37]. However, these approaches are less efficient due to
a test with low power for important scenarios. It is important to note that this approach is a shift
from the traditional paradigm where a dual estimator corresponding to a primary testing procedure
is always reported as the primary treatment effect quantifier. For example, the HR from the Cox
regression model is always presented as the dual treatment effect quantifier for the LR test.
• Step 1 (Test of null hypothesis): This step is the hypothesis testing part of primary analysis.
Treatment effect should be tested with the MaxCombo test (or modified MaxCombo test)
and conclusion regarding the null hypothesis is drawn accordingly. If the MaxCombo test
is not significant, one concludes that the benefit of experimental treatment has not been
demonstrated.
• Step 2 (Assessment of PH): Regardless of the step 1, the PH assumption of the underlying
treatment effect needs to be assessed based using different tools like Grambsch-Therneau test
or G-T test [38] based on the scaled Schoenfeld residuals from a Cox model and other visual
diagnostics (KM plot, hazard plot, log-log survival plot).
• Step 3 (Treatment effect summary): The treatment effect quantifiers will depend on the out-
come of Step 2
– If PH assumption is reasonable: report the HR from Cox regression and corresponding
95% confidence interval (CI) as the primary treatment effect measure. The milestone
survival rates are also useful treatment effect quantifiers in this context.
– If PH assumption is not reasonable: In this situation, one summary measure fails to
explain the overall treatment effect. We recommend presenting more than one treatment
effect quantifiers, such as:
∗ Ordinary HR estimate (treatment vs control) and 95% CI from the Cox regression
∗ Difference in milestone survival rate (treatment vs control) and 95% CI at clinically
relevant time point t∗
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∗ Difference in RMST (treatment vs control) at t∗ and 95% CI: gain in life expectancy
at the minimum of the maximum observed survival in treatment and control group
We also recommend to report the Kaplan-Meier plot, the milestone survival rates at additional
time points, the piecewise HR and the net benefit as supportive measures. These measures are
useful to understand the time dependent treatment profile and communicate to non-statisticians
easily. Alternatively, one can use CoxTD and provide the time dependent HR along with 95 % CI
[19].
For completeness, one can also look into the WHR estimate (treatment vs control) and 95% CI
using the best weight chosen by MaxCombo and using weighted Cox regression. It is the dual mea-
sure of MaxCombo test. Alternatively, one can report average hazard ratio proposed by Schemper
et al 2009 [39] and Xu & O’Quigley 2000 [40]. However, the WHR has limited interpretation to
non-statisticians. Similar to the p-value, the 95% CI corresponding to the estimated WHR using
the best weight from MaxCombo test needs to be adjusted due to the positive correlation be-
tween four WLR test statistics. A simultaneous confidence interval procedure by using asymptotic
multivariate normal joint distribution of WHR is provided in Appendix B.
Given the complexity of the NPH (e.g., delayed effect, crossing survival), the p-value from
step 1 or a single summary statistic fails to capture the treatment benefit. Especially, scenarios
with crossing survival require a careful evaluation and consideration of other factors such as the
timing of crossing, treatment effect after crossing, and overall risk-benefit profile. Due to the late
emerging nature of the treatment effect, it is critical to follow patients for sufficient time to get
reliable estimate of long-term benefit. In the unlikely extreme scenarios (e,g, severe late crossing
in subsection 2.1.2), totality of the data will not support the approval of a new medication to
the market despite a positive p-value. Our proposed step-wise approach chooses the appropriate
treatment summary measures based on the situation and provides a totality of evidence for making
optimum decision for an experimental drug.
2.3 Examples
We have provided three published clinical trial examples to demonstrate the utility of the Max-
Combo test and the proposed primary analysis strategy in confirmatory trials. These examples are
based on enrollment, follow-up assumptions, and high early event rate that are commonplace for
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trials in metastatic cancer. The examples include scenarios with crossing survival, delayed effect,
and proportional hazards. The purpose of this exercise is to demonstrate the utility of the proposed
approach for primary analysis to the practitioners. We have no intention to comment or judge the
clinical activity of the treatments involved or any related regulatory decisions.
The first example is the Phase III trial (IM211) of atezolizumab vs chemotherapy in patients
with advanced or metastatic urothelial carcinoma [41]. For this exercise we have considered the
overall survival (OS) endpoint for the patients in the intention-to-treat population and with >
1% tumour-infiltrating immune cells (PD-L1 expression: IC1/2/3). Using Guyot et al 2012 [42],
the data for analysis is reconstructed from the KM plot published in the supplementary materials
(page 20) of Powles et al 2018 [41]. The survival curves cross between 4 and 5 months and show
survival benefit of patients in atezolizumab arm. However, a stratified Cox regression analysis in
the publication shows a non-significant treatment effect (HR=0.87, 95% (0.71, 1.05)). Moreover
the median OS is 8.9 months for atezolizumab as compared to 8.3 months for chemo, a difference
of only 0.6 months.
A second example in recurrent or metastatic head-and-neck squamous cell carcinoma is the phase
III (KEYNOTE 040) trial of Pembrolizumab versus standard-of-care therapy [43]. The primary
endpoint of this trial was OS in the intention-to-treat population. Based on the KM plot published
in Cohen et al 2019 [43], the survival benefit of Pembrolizumab has emerged after 5 months.
Therefore, we consider this as an example for delayed treatment effect. Though the survival benefit
after 5 months looks promising, a traditional stratified LR have produced a marginally nominal
significant p-value (one-sided) = 0.016. A stratified Cox regression analysis shows a HR= 080 ;
95% CI (065098).
The final example satisfies the PH assumption. It is a phase III clinical trial (PA3) of Erlotinib
Plus Gemcitabine vs Gemcitabine alone in patients with advanced pancreatic cancer [44]. The pri-
mary endpoint of the trial was OS. Similar to the IM211 trial, the analysis data set is reconstructed
from the KM curve published in Fuchs et al 2014 [44]. A stratified analysis shows prolonged
survival on the erlotinib plus gemcitabine arm with a HR of 0.82 (95% CI: (0.69, 0.99) and nominal
statistically significant LR test (2-sided p-value =0.038). However, the difference in median survival
was just 0.3 months, 6.24 months in the gemcitabine plus erlotinib group compared to 5.91 months
in the gemcitabine alone group. The estimated effect size poses some question related to clinical
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relevance of the combination in terms of survival benefit.
We start our analysis with the assessment of PH assumption for the three examples. The
estimated hazard ratio over time is plotted along with the G-T test to ensure viability of the
PH assumption (Figure 2) for three examples. A horizontal line represents a constant treatment
effect. As expected, the PH hazard assumption is doubtful except for the PA3 trial. Both graphical
diagnostics and G-T test fail to support the PH assumption for both IM211 and KEYNOTE 040
trials.
[Figure 2 about here.]
Therefore, the traditional summary measures (e.g., Median, HR) fail to measure the treatment
effect fully except for the PA3 trial. We have analyzed all the examples with MaxCombo, rank-
based tests (LR and WLR), KM based tests (WKM, RMST, and RTML), difference in milestone
rates at month 12 (clinically relevant time point), and % net benefit for > 6 months longer survival.
For KM based methods, we have minimum of the largest observed time in each of the two groups
as a choice of τ . For nominal statistical significance, the p-value from each test is compared at
one-sided 2.5% level of significance. In addition, we have calculated the milestone survival rates at
additional time points (at 3, 12, 18 and 24 months) and piecewise HR (intervals: 0- 3 months, 3-
6 months, 6-12 months and > 12 months) to understand the treatment effect over time. Table 2
summarizes the analysis of OS for IM211, KEYNOTE 040, and PA3. As data set for two of the
examples are re-constructed from published KM plots, we do not have the relevant stratification
factors used for publication. Therefore, all the analyses in this section are unstratified.
[Table 2 about here.]
For the crossing survival scenario in IM211, Table 2 shows nominal significant result for the
MaxCombo test (p-value= 0.005) only. All other tests fail to reject the null hypothesis in spite
of potentially clinically relevant improvement of OS at the later stage. Therefore, one can miss
a potential regulatory submission opportunity if the primary analysis is the LR test or other KM
based tests. The MaxCombo chooses G0,1 as the minimum p-value. As the diagnostic plot and
result from the GT test (p value=0.02) questions the PH assumption, we recommend reporting the
HR (estimate= 0.847, 95% CI= (0.70, 1.02)), difference in milestone rates at 12 months (estimate=
14
0.021, 95% CI = (-0.04, 0.18)) and difference in RMST (estimate= 1.09, 95% CI=(-0.22, 2.40)))
as treatment effect quantifiers in this case. HR and difference in RMST show a positive trend in
favor of treatment. The overall evidence supports a clinically relevant treatment effect. Additional
supportive analyses (e.g., milestone survival rate estimates at multiple timepoints, piecewise HR,
WHR and % net benefit) are useful to provide further confirmation of treatment benefit. Figure
3 shows the milestone survival estimates and piecewise HR’s. Both capture the time-dependent
treatment effect in an efficient manner. Difference in milestone survival rates at early and late
timepoints show a survival benefit of atezolizumab over chemotherapy.
In KEYNOTE 040 trial, the treatment effect emerges late. Note that the published LR test
p=0.016 was from a stratified analysis as compared to p-value=0.007 reported in Table 2 from a LR
test without stratification. Similarly, stratified results for the MaxCombo test yields p-value =0.003
compared to a unstratified MaxCombo test with p-value =0.001 as reported in Table 2. Thus,
the stratified test was particularly important to clarify nominal statistical significance compared
to the stratified LR test. Based on diagnostics plots (Figure 2) and GT test, there are some
evidence of NPH. The HR over time plot challenges the constant HR assumption. Therefore, we
have applied two strategies to understand the robustness of treatment effect. As a first step, the
MaxCombo suggests stronger evidence of a treatment difference (p=0.001) than LR test. As a
next step, we looked into HR from Cox regression (estimate=0.78; 95% CI (0.64, 0.95)) and KM
medians (8.4 months (treatment) vs 6.9 months (control)) as key treatment effect summaries. As
the PH assumption is doubtful from the diagnostics (Figure 2), we also looked into the RMST
(estimate= 1.9; 95% CI (0.39, 3.41)) and difference in month 12 milestone rates (estimate=0.09;
95% CI (-0.02, 0.22)). Furthermore, the treatment effect is confirmed by the positive difference
in milestone survival rates at early and late timepoints. Finally the piecewise HR plot shows a
positive trend for survival benefit in favor of Pembrolizumab after first 3 months.
Finally for the PA3 trial, the LR test becomes statistically significant (one sided p-value =0.023)
with a modest or clinically questionable treatment effect (HR= 0.834 with 95% CI = (0.70, 0.99) or
median difference of 0.33 months). The MaxCombo test fails to meet nominal statistical significance
(p-value= 0.048) which is consistent with other tests (e.g., WKM, RMST). This is primarily due to
the multiplicity adjustment for the different test statistic in MaxCombo. However, caution should
be used when applying the MaxCombo test if NPH is not anticipated.
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[Figure 3 about here.]
The three examples above show the utility of the MaxCombo test and primary analysis approach
when NPH is a possibility. It is evident that MaxCombo has benefit in case of delayed effect and
crossing scenario survival scenarios. When the PH assumption is violated, the current regulatory
standard of declaring a study positive or negative based on a single p-value (from the LR test)
and estimating the treatment benefit using a single dual summary measure (HR from the Cox
model) can be problematic. This suggests the value of a robust testing approach such as the
MaxCombo and adaptive primary analysis strategy. It is also evident that a single measure such
as the HR is not adequate to describe the treatment benefit when PH assumption is violated.
Additional measures such as piecewise HR, milestone survival and difference in RMST are essential
for adequate description of treatment differences.
3 Design Approaches for Clinical Trials with Non-proportional
Hazard
In this section, we have discussed a design approach for a confirmatory trial with the MaxCombo
test. When NPH is a possibility, a confirmatory trial design needs to consider the uncertainty
about the type of treatment effect. If a MaxCombo test is used for the primary testing, it is
important that the sample size and total follow-up time of a trial ensure adequate power for the
most likely treatment effect type under a reasonably conservative alternative hypothesis. Therefore,
a carefully elicitation of the possible treatment effect type (e.g., delayed effect, crossing survival
etc.) is important at the design stage. Often a confirmatory trial involves interim analysis for early
stopping due to futility or overwhelming efficacy. Group sequential methods are popularly used
in this context. A notable work regarding the use of group sequential design in trials with NPH
includes Logan and Mo 2015 [45]. However, the key question is how to plan for interim analysis in
a design with MaxCombo as primary analysis? Although the group sequential strategies are well
understood using LR test in the PH setting, little attention has been given to their performance
when the effect of treatment varies over time. We present an interim stopping strategy when the
MaxCombo test is the proposed primary testing.
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3.1 Sample Size Calculation
Under PH, the number of events determines the power of a design. But if the PH assumption is
violated, enrollment rate, number of events, trial duration and total follow-up time play important
roles in the power calculation. The final analysis timing based on the accumulation of events only
may produce a design that finishes too early, is under-powered and failed to describe the impact of
treatment over time. Therefore, a good design strategy with potential NPH needs to find a balance
between the number of events (or sample size) and trial duration. A smaller sample size with fewer
events but longer follow-up can provide more power and a better description of late behavior of the
survival distribution than a larger sample size trial with short follow-up time. Unlike the LR test,
a closed form expression for the sample size calculation and trial duration is not available for the
MaxCombo test. Therefore, we propose a two-step approach for sample size calculation using an
iterative procedure when the MaxCombo test is proposed for the primary testing of hypothesis.
1. Determining minimum follow-up time (sample size time trade-off): First assume an
enrollment duration and vary the minimum follow-up time for each patient after enrollment
to optimize perceived trade-offs between sample size and trial duration. A general recom-
mendation for minimum follow-up time is twice the median of control arm. However, this
can vary for different settings.
2. Adjusted level of significance: The MaxCombo test consists of four positively correlated
Fleming-Harrington WLR test statistics. Therefore, the sample size calculation requires an
adjusted significance level for each test to protect the overall type I error at a desired level
(e.g. 2.5%). We propose an adjusted level of significance calculation based on the asymptotic
multivariate distribution of G0,0 , G0,1, G1,0, and G1,1 [27]. This method requires the
knowledge of correlation matrix between Fleming-Harrington WLR test statistics under the
null hypothesis (equality of survival distribution). To estimate the correlation matrix, we
simulate a trial with large sample size (≥ 1000) and with given enrollment and minimum
follow-up time (determined in the previous step) for each patient. Here we generate data for
treatment and control arms using piecewise exponential distributions with control event rate
(under null). The correlation matrix is approximated by the empirical correlation matrix
calculated from this large trial under the null hypothesis, given enrollment and follow-up
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time. This approach is efficient from a computational aspect and provides good estimate
of the correlation matrix due to large sample theory. Finally, the statistical significance
boundary for each component of the MaxCombo test is calculated by solving for a nominal
Z-value of the multivariate distribution with mean zero and the correlation matrix resulting
from the above simulation.
3. Sample size calculation After establishing the minimum follow-up time and adjusted level
of significance, we use a minor modification of Hasegawa 2014 [46] to obtain the sample size
and the required number of events for each component of the MaxCombo test at the adjusted
significance level computed above. The minimum of these four numbers is chosen as the
initial sample size and number of events. The final sample size, number of events and trial
duration needs an iterative approach to confirm whether the design has type I error control
and adequate power under alternative hypothesis scenarios of greatest interest (e.g., PH with
minimal effect of interest and most conservative delayed effect alternative).
If the operating characteristics are not adequate, the previous steps need to be repeated. Both
the number of events and the minimum follow-up time need to be adjusted. This procedure
continues until an acceptable power and type I error control are achieved.
The adjusted significance level is often twice that of an overly conservative Bonferroni correc-
tion, resulting in a smaller sample size requirement. In final analysis the p-value of MaxCombo
test will be compared with the nominal p-value boundary (e.g., 2.5% for one-sided p-value). For
a confirmatory trial, we propose to include at least two treatment effect scenarios in the study
protocol: a PH scenario and an expected NPH scenario for power calculation. With the assumed
enrollment rate, minimum follow-up time, number of events and sample size calculated using the
steps mentioned above, it is important to demonstrate good operating characteristics in both the
scenarios. This establishes the robustness of power for the MaxCombo test when the actual type
of NPH is uncertain. More than one NPH scenario can be included based on the perceived needs
at the design stage. A high level summary of the necessary steps for sample size calculation are
provided in Figure 4.
[Figure 4 about here.]
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3.2 Interim Analysis
Planning interim analysis requires a cautious approach when NPH is a possibility. Especially, for
later emerging treatment effect scenarios (e.g., delayed effect or crossing survival) one needs to
reconsider the traditional implementation of interim analyses. An early interim analysis will have
smaller probability of stopping for efficacy and higher probability of crossing any futility bound
under a delayed effect or crossing hazard scenario. On the other hand, if an interim analysis is
too late, it may not be useful. While planning for interim analysis with potential NPH, it is
important to find a balance between the risks of stopping too soon before late benefit emerges and
the appropriately monitoring of the trial for futility. Thus, selection of interim analysis timing
should consider both number of events and total follow-up.
Available statistical literature regarding interim analysis with NPH is still small. A group
sequential test for WLRT, WKM and combination of LRT & Nelson Allen have been discussed by
Hasegawa 2016 [47] and Logan & Mo 2016 [45] . In this paper, we introduce a group sequential
design strategy for planning interim analysis in a confirmatory trial when the primary testing is
planned with the MaxCombo test. It incorporates both efficacy and futility bounds. For interim
analysis, we propose using the LR test statistic. The three primary reasons for the recommendation
are: i) to avoid the impact of shorter follow up time or trial duration in Fleming-Harrington WLR,
ii) traditional interim boundaries based on the LR test are well accepted by regulatory authorities,
and iii) using a more robust test at final analysis when data are mature to detect important benefits.
The final success boundary needs multiplicity adjustment due to the correlation between the LR
test at interim and the MaxCombo test at the final analysis. We use the independent information
increment assumption [48] and asymptotic multivariate distribution of interim LR test statistic
and final MaxCombo test statistic to calculate the final analysis boundary. A detailed formula for
the correlation matrix with one interim analysis and calculation of boundary for the final analysis
are provided in appendix C. The final boundaries and correlation matrix are calculated based on
actual number of observed event and follow-up. An example of the boundary calculation is provided
in next subsection.
Incorporating interim analysis for stopping in a design requires important statistical and opera-
tional considerations apart from the boundary calculation. This includes timing of interim analysis,
probability of stopping, impact on the power, and overall benefit-risk etc. These aspects are out
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of scope for this paper. For timing of the efficacy interim, we recommend complete enrollment,
accrual of at least 65-70% of the planned events, and at least 6 months follow-up after last patient
enrolled. An early futility analysis is problematic when treatment effect is emerging late. Therefore,
we recommend statisticians not to perform futility analysis before 45-50% of planned events are
accrued unless there is a safety issue. The recommendation is to stop the trial if and only if the
treatment seems harmful (e.g. HR > 1.5).
3.3 Example
In this subsection, we show an example of sample size calculation in a protocol for two arms
(treatment vs control) randomized trial with a time to event endpoint. As mentioned above,
when NPH is a possibility both trial duration and number of events are important components
of the sample size section of the protocol. Furthermore, we assume that based on the mechanism
of treatment and evidence from early stage, there is a possibility for delayed effect. However,
considerable uncertainty is associated with the occurrence of NPH and the lag time until treatment
benefit emerges. This is a common phenomenon for immuno-oncology.
We will assume 15 months of constant enrollment, a constant dropout rate of 0.001 per month,
control group observations follow an exponential survival distribution with a median of 8 months.
After careful elicitation of all available evidence, we assume a possible delayed treatment effect
scenario (alternative hypothesis): no treatment effect for 6 months (HR=1), followed by a large
treatment effect (HR= 0.56) thereafter. As this is a confirmatory trial for potential regulatory
submission, strict control of 2.5% type I error is required, and those investing in the study wish to
ensure 90% power under this NPH scenario. Below are the two steps for sample size calculation:
1. The first step is specification of the minimum follow up time for each patient or trial duration.
We consider total trial duration of 18, 24, 32 and 40 months to compare required sample size
for each component of the proposed MaxCombo test (Table 3). All sample sizes are calculated
using the method of Hasegawa 2014 [46].
[Table 3 about here.]
We note two things in the Table 3. First, the G0,1 always results in the smallest sample size
and event count requirement among the four WLR tests. Second, we select a study duration
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of 32 months (15 months enrollment + 17 months follow-up after last patient enrolled) given
the steep increase in sample size for smaller trial duration and allowing more than twice the
control arm median for minimum follow-up time.
2. We generate the time to event data for 5000 patients (2500 per arm) using an exponential
distribution with median 8 months (under null). The correlation matrix for four Fleming-
Harrington WLR test statistics is estimated using the empirical correlation from the large
trial. Now using a grid search, the statistical significance boundary for MaxCombo is -2.286
with a nominal standard normal p-value of 0.011.
3. Next step is calculating the sample size and the number of events separately for the four
components of MaxCombo test using the Hasegawa 2014 [46]. This calculation includes a)
trial duration of 32 months, b) a drop-out rate of 0.001, c) specific delayed treatment effect
alternative stated above, d) level of significance 1.1% (calculated in step 2), and e) target
power of 90%. As the chosen NPH alternative reflects delayed treatment effect, G0,1 yields
the minimum sample size and number of events. Therefore, the initial sample size of the trial
is 442 with a target accrual of 360 events.
We confirm type I error and power using simulation under alternate hypotheses of interest.
The initial sample size meets the type I error and power requirement based on 10000 simula-
tions. We further assessed the power of MaxCombo under a PH scenario. The power of the
proposed design under proportional hazards with HR=0.692 is 88.6%.
Hence, the final analysis of the trial is planned after the accumulation of 372 events or 16 months
after the last patient enrolled whatever happens last. The final sample size of the trial is 472. This
represents considerable savings in sample size relative to the traditional LR test (690 patients and
544 events). Further details of the sample size calculation including correlation matrix for null
distribution are provided in Appendix D.
Now, we add an interim analysis in the design to illustrate the calculation of analyses boundaries.
We consider a single interim analysis for simplification. for example, an interim analysis is planned
in this trial after a) enrollment is complete, b) at least 65% events are observed, and c) at least 6
month of follow-up after enrollment is complete. The actual interim is performed after 270 events
(75% of the planned events). The interim boundary for efficacy is calculated by using the traditional
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alpha-spending function with O’Brien Fleming type boundary [49]. The interim efficacy boundary
is -2.34 in Z-scale or 0.0096 in p-value scale. The final analysis boundary requires the correlation
matrix between the interim LR test statistic and the four components of MaxCombo test under the
null hypothesis. Lastly, we did a grid search of the final analysis cutoff that preserves the overall
total type I error at 2.5%. The Z-value cutoff for final analysis is -2.305. Additional details are in
Appendix D.
4 Conclusion and Discussion
The development plan for each experimental drug is unique. Current design and analysis approaches
of a confirmatory clinical trial with a time to event endpoint depend heavily on the proportional
hazards assumption which is questionable in many situations. Traditional approaches are less
efficient when the treatment effect is not constant. Non-constant effects like delayed effect or
crossing survival, are often observed. It is important to propose a flexible and robust primary
analysis strategy to cope with possible treatment effect patterns. Many authors have proposed
statistical methods for analyzing clinical trials when the PH assumption is violated. However, none
of them are robust enough to have adequate power for wide number of NPH scenarios [18] which
is critical in practice due to the uncertainty related to possible NPH types at design stage.
We propose a robust statistical approach for primary hypothesis testing in a confirmatory clin-
ical study with a time to event endpoint. The proposed methodology is flexible and adaptive
enough to provide good statistical properties under PH and different types of NPH. The proposed
MaxCombo test is a combination of four Fleming-Harrington WLR tests which can handle dif-
ferent treatment effect patterns. The operating characteristics [18] including type-I error control
and illustrative examples demonstrate the utility of the MaxCombo test. The test shows clear
advantages when a large treatment benefit emerges later on in the trial (PH with marginal effect,
delayed effect and crossing hazard scenario in Section 2.3). The PH scenario (digitized PA3 trial
data) shows a possible downside of the MaxCombo test as a marginally positive LR test in a case
that reflects proportional hazards would have been a close miss if the MaxCombo test had been
utilized. While one could argue that the survival benefit was minimal, it was an overall survival
benefit for pancreatic cancer, an indication where the authors point out that progress in treatment
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options has been slow. The ultimate value of the treatment for patients may depend on trade-offs
between toxicity and secondary efficacy endpoints. For trial designers, this should point out that
the MaxCombo test might not be optimal if there is a strong reason to believe that the benefit
from a new treatment will be immediate and sustained. This assumption generally would not
be made for immunotherapies or, say, chronic treatment of diabetes or lipids to reduce long-term
cardiovascular risk.
Following the recent criticism about the WLR tests [12], [35], we have performed additional
simulations to evaluate the MaxCombo test under some extreme scenarios such as strong null [12],
[35] and one severe crossing hazard. The simulation shows a high probability of rejecting null
hypothesis for the MaxCombo test under strong null 2. However, such scenarios can be handled
with the modified MaxCombo test. Note that, these scenarios (specially strong null 2) are unlikely
in real life and will result in the trial getting stopped early by a data monitoring committee (DMC)
due to the safety concerns.
We have proposed a stepwise approach for reporting the treatment effect quantifiers depending
on the validity of PH. Though HR is sufficient under PH, a single summary measure is not adequate
when the treatment benefit is not constant over time. We recommend trialists to report additional
measures like milestone survival rates and RMST as primary treatment effect quantifiers when
the PH assumption is questionable. This is different from current practice. The adaptive nature
of the proposed approach helps to choose most appropriate summary measures for describing the
treatment effect. This provides statisticians the required flexibility while being compliant with ICH
E9 guidance [33]. When PH is violated and a difference is established using the MaxCombo test,
additional measures such as WHR, piecewise HR, milestone survival and difference in RMST are
useful in interpreting the trial results. There is a possibility that the WHR overestimates treatment
effect in some situations by allowing high weights on the tail events. Therefore, the other supportive
measures are important to understand the complete picture. However, a traditional summary
measure such as HR may be adequate when the PH assumption is reasonable.
The second part of the paper introduces a design approach for confirmatory trials with the
MaxCombo test. We have developed a stepwise and iterative approach for calculating sample size
when the final analysis is based on MaxCombo test. In contrast to the LR test, the design approach
with the MaxCombo test needs to consider both the number of events and total follow up time for
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good statistical operating characteristics (type I error and power). The study protocol needs to
state all the requirements along with a detailed simulation plan for assessing the design operating
characteristics. We have provided a detailed examples and R codes to help the practitioners.
The design approach uses the asymptotic joint distribution of four Fleming-Harrington WLR tests
which is more efficient than other conservative multiplicity adjustments or LR test alone. We have
also proposed a simple yet effective interim analysis procedure for early stopping for efficacy. As
adequate closed form formulas are not available, simulation plays an important role at the design
stage. Efficient R packages (e.g. nphsim or simtrial) [50] can be useful in this context. Examples
of design and analysis using nphsim and simtrial are provided in the supplementary materials.
Finally, in this paper we have discussed possible analysis and design for a confirmatory trial. The
proposed approach is intended to improve study design and appropriate discussion about advance-
ment of new therapies that may currently not be considered due to overly restrictive expectations
on statistical testing.
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Appendix A: Combination test and Calculation of p-value
The proposed combination test
Zmax = max{Gρi,γj : (ρi, γj) = (0, 0), (0, 1), (1, 0), (1, 1)}
Using the result from Karrison et al. 2016 [27], the asymptotic null distribution of four WLR
test statistics follows a multivariate distribution with mean 0 and correlation matrix Γ:
(G0,0, G0,1, G1,0, G1,1) ∼ N4(0, Γ)
With correlation matrix Γ=((ηij)) is of the following form;
ηij =
Cov(Gρi,γi , Gρj ,γj )√
V (Gρi,γi)V (Gρj ,γj )
=
V (G
ρi+ρj
2
,
γi+γj
2 )√
V (Gρi,γi)V (Gρj ,γj )
for i 6= j
= 1 for i = j
Therefore, the one-sided p-value of MaxCombo test is calculated using a multivariate normal
calculation given below:
P (Zmax > zmax|H0) = P (max(G0,0, G0,1, G1,0, G1,1) > zmax|H0)
= 1−
∫ zmax
−∞
∫ zmax
−∞
∫ zmax
−∞
∫ zmax
−∞
φ4(ω,0,Γ)dω
zmax is the observed value of MaxCombo test statistic and φ is the pdf of 4-dimensional mul-
tivariate distribution. The power calculation of MaxCombo does not have a closed expression.
Therefore, a simulation approach is required for power calculation. Supplementary material con-
tains an example R codes for calculating p-value of the MaxCombo test and corresponding adjusted
95% confidence interval using nphsim package.
Appendix B: Calculation of Simultaneous Confidence Interval
Let, HRMaxCombo is the estimated WHR using the best weight as per MaxCombo and using
weighted Cox regression [51]. Therefore, a 100× (1− α)% simultaneous confidence interval corre-
sponding for WHR related to MaxCombo can be calculated asHRMaxCombo ± C∗×SE(HRMaxCombo).
SE(HRMaxCombo) is the standard error of HRMaxCombo and C∗ is calculated using the asymptotic
multivariate normal distribution of WHR [27].
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Appendix C: Calculating interim and final boundaries with one
interim analysis
Let t be the fraction of events at interim over planned event count at final analysis. G0,0(t),
G0,0(1), G0,1(1), G1,0(1), and G1,1(1) are the LR test statistic at the interim analysis and test
statistics of the MaxCombo test at the final analysis (LR test, (FH(0,0), FH(0,1), FH(1,0), and
FH(1,1) respectively).
Zmax = max{G0,0(1), G0,1(1), G1,0(1), G1,1(1)}
Now, the correlation between G0,0(t) and Gρ,γ(1); ρ, γ = 0, 1 can be calculated using indepen-
dent increment [48] and Karrison 2016 [27]
cov(G0,0(t), Gρ,γ(1)) = cov(G0,0(t), Gρ,γ(t)) assuming independent increment
= var(G
ρ
2
, γ
2 (t))
Therefore, the correlation between G0,0(t) and Gρ,γ(1)
corr(G0,0(t), Gρ,γ(1)) =
V (G
ρ
2
, γ
2 (t))√
V (G0,0(t))× V (Gρ,γ(1))
The boundary for the final analysis (zFmax) must satisfy the equation below;
P (ZI > zI |H0) + P (ZI ≤ zI , ZFmax > zFmax|H0) ≤ 0.025
Here ZI , zI , and Z
F
max are LR test statistic at interim analysis, interim efficacy boundary, and
MaxCombo test statistic for final analysis. zI is determined by well-known spending functions (e.g.,
O’Brien-Fleming) and zFmax can be solved using a grid search.
Appendix D: Details of Example in Section 3.3
I Details of Sample Size Calculation without Interim Analysis
The estimated correlation matrix of the null distribution based on simulation steps described
in Section 3.3
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ΓH0 =

1.000 0.864 0.913 0.940
0.864 1.000 0.583 0.892
0.913 0.583 1.000 0.792
0.940 0.892 0.793 1.000

Therefore, the boundary for MaxCombo (Zcutoff ) is obtained by solving the equation below;
Φ4(Zcutoff ,0,ΣH0) ≤ 0.025
Φ4 is the CDF of 4-dimensional multivariate normal distribution. This yields Zcutoff = -
2.286. Now, the calculation of sample size for four components of the MaxCombo test uses
a) level of significance 1.11%, b) target power of 90%, c) constant enrollment for 15 months,
d) follow-up for 17 months after last patient enrolled, d) dropout rate 0.001 patients per
month, and d) alternative hypothesis: no treatment effect (HR=1) for first 6 month followed
by clinically meaningful treatment effect (HR=0.56). The sample size for each test is given
in Table 4 below:
[Table 4 about here.]
Therefore, the final analysis of the trial is planned after the accumulation of 372 events or
16 months after the last patient enrolled whatever happens last. The final sample size of the
trial is 472.
II Details of Interim and Final Analysis Boundary Calculation
The correlation matrix for interim LR test statistic and four Fleming Harrington WLR test
statistic for final analysis is
ΓHI =

1.000 0.858 0.565 0.926 0.769
0.858 1.000 0.863 0.930 0.940
0.565 0.863 1.000 0.617 0.922
0.926 0.930 0.618 1.000 0.794
0.768 0.940 0.922 0.794 1.000

Therefore the final boundary (zF ) can be calculated using a grid search to solve for
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P (ZI < −2.34|H0) + P (ZI > −2.34,MF < zF |H0) ≤ 0.025
The interim stopping boundary (zI = -2.34) is calculated using the Lan-DeMets (OBrien-Fleming)
α-spending function. Supplementary material contains an example R code for sample size and
interim analysis boundary calculation.
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Figure 1: Simulation scenarios for evaluation of MaxCombo under strong null and severe late
crossing
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Figure 2: Schoenfeld Residual Plots for Three Examples: a) IM211: Digitized (top left), b)
KEYNOTE 040 (top right), c) P A3: Digitized (bottom)
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Figure 3: Milestone Survival (95% CI) and Piecewise Hazard Ratio (95% CI) at Clinically Relevant
Time points for Three Trials
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 • Enrollment rate  
• Potential NPH scenario(s) 
•  
Assumptions 
• Trade-off between sample size and timing: need to evaluate impact of 
follow-up on sample size 
• General recommendation: twice of the control group median 
Step 1: Determining Minimum Follow-up Time  
• Empirical estimation of the correlation matrix of G0,0,  G0,1, G1,0, G1,1 
under null hypothesis (no treatment effect) via simulation  
• Using multivariate normal distribution to calculate the adjusted level of 
significance for individual test 
Step 2: Adjusted Level of Statistical Significance 
• Calculate sample size for all four tests using adjusted level of 
significance (previous step) and potential NPH scenario (s) as alternative 
• Sample size calculation is done using piecewise hazard approximation 
(Hasegawa 2014) 
Step 3: Initial Sample size Calculation   
Initial S mple size Calculation   
 
• Simulation study to confirm that the MaxCombo test has adequate 
power and type-I error control for sample size determined above 
• Iteratively adjust sample size until the operating characteristics are 
satisfactory 
Step 4: Confirmation 
Initial Sa ple size Calculation  
 
Figure 4: Overview of Sample Size Calculation
38
List of Tables
1 Review of Different Approaches for Analysis of Time to Event Data Under NPH . . 40
2 Analysis of Overall Survival for IM211 (Digitized), KEYNOTE 040, and PA3 (Dig-
itized): Results of Different Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3 Required Sample Size for Four Components of The MaxCombo Test under Different
Trial Duration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
4 Sample Size for Four Components of the MaxCombo Test . . . . . . . . . . . . . . . 43
39
Table 1: Review of Different Approaches for Analysis of Time to Event Data Under NPH
Method Type I Robust Treatment Effect Non-statistical
Error Power Interpretation Communication
Rank-based Test
Log-rank Test/Cox Model Yes No No Yes
Fleming Harrington weighted Yes No No No
Log-rank Test/Weighted Hazard Ratio
Piecewise Log-rank Test/ Yes No Yes Yes
Modestly weighted Log-rank Test/
Piecewise Hazard Ratio
Kaplan-Meier based Test
Milestone Survival Yes No Yes Yes
Kaplan-Meier Median - - No Yes
Weighted KM test Yes No No No
RMST Yes No Yes Yes
Cox model with time varying Yes No Yes No
treatment effect (CoxTD)
Combination test Yes Yes Yes No
Net Benefit Yes No Yes Yes
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Table 2: Analysis of Overall Survival for IM211 (Digitized), KEYNOTE 040, and PA3 (Digitized):
Results of Different Methods
Method IM211: Digitized KEYNOTE 040 PA3: Digitized
(Crossing) (Delayed Effect) (PH)
Kaplan-Meier Median (months)
Treatment 8.9 8.4 6.24
Control 8.3 6.9 5.91
Log-rank Test
p-value 0.040 0.007 0.023
Cox HR 0.847 0.778 0.834
95% CI (0.70, 1.02) (0.64, 0.95) (0.70, 0.99)
Fleming Harrington WLR Test: p-value
G1,0 0.216 0.068 0.047
G1,1 0.004 0.001 0.064
G0,1 0.002 0.001 0.031
Max Combo
Test selected G0,1 G0,1 G0,0
p-value 0.005 0.001 0.048
Weighted HR 0.731 0.681 0.834
95% CI (0.57, 0.93) (0.52, 0.89) (0.68, 1.03)
RMST
Difference 1.090 1.900 0.860
95% CI (-0.22, 2.40) (0.39, 3.41) (-0.07, 1.79)
p-value 0.051 0.007 0.034
RTML
Ratio 0.920 0.891 0.942
95% CI (0.83, 1.02) (0.81, 0.98) (0.88, 1.01)
p-value 0.052 0.008 0.036
Weighted KM Test: p-values 0.129 0.024 0.034
% Net Benefit at Month 6
Difference 0.052 0.085 0.086
95% CI (-0.04, 0.14) (-0.014;0.19) (-0.02, 0.18)
p-value 0.286 0.106 0.083
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Table 3: Required Sample Size for Four Components of The MaxCombo Test under Different Trial
Duration
Number of Events/Sample Size
Trial duration G0,0 G0,1 G1,0 G1,1
(months)
18 1699/3160 709/1318 4028/7496 1002/1864
24 755/1094 394/570 1829/2650 525/760
32 511/628 296/364 1392/1712 399/490
40 439/496 268/302 1329/1502 372/420
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Table 4: Sample Size for Four Components of the MaxCombo Test
Test Sample Size Event
G0,0 828 653
G0,1 472 372
G1,0 2190 1726
G1,1 630 497
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